These findings suggest that TPA or mezerein activates the expression levels of Hmga2 in Bhas42 cells during CTAs, indicating a molecular target for tumour progression activation in Bhas42 cells exposed to NGCs. The gene discussed is HMGA2; the disease is neoplasm.